52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Sept 30 (Reuters) - Moberg Pharma AB (publ) <MBPH.ST>::MOBERG PHARMA AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR MOB-015 IN JAPAN.MOBERG PHARMA- ELIGIBLE TO RECEIVE MILESTONES OF UP TO $50 MILLION CONTINGENT ON DEVELOPMENT & COMMERCIAL SUCCESS, AS WELL AS SUPPLY FEES INCLUDING ROYALTIES..MOBERG PHARMA AB - MAJORITY OF MILESTONE PAYMENTS ARE CONTINGENT ON SALES TARGETS, WITH BALANCE CONTINGENT ON DEVELOPMENT AND REGULATORY MILESTONES..
July 2 (Reuters) - Japan's Taisho Pharmaceutical <4581.T>::COMPLETES PROCEDURES FOR ACQUISITION OF UPSA SAS.
Dec 19 (Reuters) - Japan's Taisho Pharmaceutical Holdings Co Ltd <4581.T>::TO BUY UPSA FOR $1.6 BILLION FROM BRISTOL-MYERS.
Dec 16 (Reuters) - :TAISHO IS SAID TO NEAR $1.6 BILLION DEAL FOR BRISTOL-MYERS'S UPSA UNIT - BLOOMBERG, CITING SOURCES.
June 27 (Reuters) - Biofermin Pharmaceutical Co Ltd <4517.T>:Says it names Hideyuki Waki as president, effective June 27 .
June 28(Reuters) - Biofermin Pharmaceutical Co Ltd <4517.T>:Says it appoints Ken Uehara as new chairman.Effective June 28.
Dhg Pharmaceutical Joint-Stock Co <DHG.HM> : Vietnam's Dhg Pharmaceutical Co says Q2 net profit down 1.3 percent y/y at 147 billion dong ($6.6 million) Further company coverage: [DHG.HM] (Reporting By Mai Nguyen) ((firstname.lastname@example.org;)).
Taisho Pharmaceutical Holdings Co Ltd <4581.T>:Says its unit Taisho Pharmaceutical signed agreement (contract for the license and commercialization) for an allergic disease therapeutic agent regarding OTC drugs in Japan with Bayer Yakuhin, Ltd., on July 11.
Taisho Pharmaceutical Holdings Co Ltd <4581.T>: Says its unit acquired 24.5 percent stake in Vietnam-based co Duoc Hau Giang Pharmaceutical JSC on July 4 .Says Duoc Hau Giang Pharmaceutical JSC engaged in Pharmaceutical manufacturing and sale, sale of functional food.
TAISHO PHARMACEUTICAL HOLDINGS Co Ltd:Says the company increased the consolidated mid-year outlook for revenue to 146,000 mln yen from 144,000 mln yen, for the fiscal year ending March 2016.Operating profit forecast increased to 13,900 mln yen from 10,000 mln yen.Ordinary profit forecast increased to 17,700 mln yen from 14,000 mln yen.Net profit forecast increased to 11,300 mln yen from 8,500 mln yen.Earnings per share increased to 139.39 yen from 104.86 yen.Comments improvements in core business and cost reduction are the main reasons for the forecast.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.